306 related articles for article (PubMed ID: 16390779)
21. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
22. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome.
Khorram O; Helliwell JP; Katz S; Bonpane CM; Jaramillo L
Fertil Steril; 2006 May; 85(5):1448-51. PubMed ID: 16579997
[TBL] [Abstract][Full Text] [Related]
23. [Diagnosis and treatment of polycystic ovary syndrome].
Gandar R; Spizzo M; Collin D
J Gynecol Obstet Biol Reprod (Paris); 1999 Oct; 28(6):510-8. PubMed ID: 10598343
[TBL] [Abstract][Full Text] [Related]
24. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
Panidis D; Rousso D; Koliakos G; Kourtis A; Katsikis I; Farmakiotis D; Votsi E; Diamanti-Kandarakis E
Fertil Steril; 2006 Jun; 85(6):1778-83. PubMed ID: 16650418
[TBL] [Abstract][Full Text] [Related]
25. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
Højlund K; Glintborg D; Andersen NR; Birk JB; Treebak JT; Frøsig C; Beck-Nielsen H; Wojtaszewski JF
Diabetes; 2008 Feb; 57(2):357-66. PubMed ID: 17977950
[TBL] [Abstract][Full Text] [Related]
26. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
27. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
28. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.
Rautio K; Tapanainen JS; Ruokonen A; Morin-Papunen LC
Hum Reprod; 2006 Jun; 21(6):1400-7. PubMed ID: 16501039
[TBL] [Abstract][Full Text] [Related]
29. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
Otto-Buczkowska E; Jarosz-Chobot P; Deja G
Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
[TBL] [Abstract][Full Text] [Related]
30. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women.
Ibáñez L; de Zegher F
Hum Reprod Update; 2006; 12(3):243-52. PubMed ID: 16407452
[TBL] [Abstract][Full Text] [Related]
31. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Romualdi D; Guido M; Ciampelli M; Giuliani M; Leoni F; Perri C; Lanzone A
Hum Reprod; 2003 Jun; 18(6):1210-8. PubMed ID: 12773448
[TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
Blank SK; McCartney CR; Helm KD; Marshall JC
Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
[TBL] [Abstract][Full Text] [Related]
34. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
Allon MA; Leach RE; Dunbar J; Diamond MP
Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
[TBL] [Abstract][Full Text] [Related]
35. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
37. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
[TBL] [Abstract][Full Text] [Related]
38. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
39. Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Narsing Rao L; Jacob JJ; Paul TV; Rajarathinam S; Thomas N; Seshadri MS
J Pediatr Adolesc Gynecol; 2009 Apr; 22(2):91-5. PubMed ID: 19345914
[TBL] [Abstract][Full Text] [Related]
40. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS.
Van Dam EW; Roelfsema F; Veldhuis JD; Helmerhorst FM; Frölich M; Meinders AE; Krans HM; Pijl H
Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E865-72. PubMed ID: 11882506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]